Equities research analysts forecast that Agenus Inc (NASDAQ:AGEN) will report $15.58 million in sales for the current quarter, according to Zacks. Two analysts have issued estimates for Agenus’ earnings, with the lowest sales estimate coming in at $3.56 million and the highest estimate coming in at $27.60 million. Agenus posted sales of $5.58 million in the same quarter last year, which would indicate a positive year over year growth rate of 179.2%. The company is expected to announce its next quarterly earnings results on Thursday, March 8th.
According to Zacks, analysts expect that Agenus will report full-year sales of $15.58 million for the current fiscal year, with estimates ranging from $38.08 million to $62.10 million. For the next fiscal year, analysts anticipate that the business will post sales of $28.53 million per share, with estimates ranging from $21.46 million to $35.60 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Agenus.
Several research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Agenus from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a research note on Tuesday, January 9th. BidaskClub lowered shares of Agenus from a “hold” rating to a “sell” rating in a research note on Saturday, December 9th. Finally, ValuEngine lowered shares of Agenus from a “sell” rating to a “strong sell” rating in a research note on Friday, December 29th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $5.81.
Agenus (NASDAQ:AGEN) opened at $3.65 on Friday. The company has a debt-to-equity ratio of -2.39, a current ratio of 1.55 and a quick ratio of 1.55. The stock has a market cap of $312.41, a PE ratio of -3.12 and a beta of 2.10. Agenus has a 12 month low of $3.20 and a 12 month high of $5.45.
In other Agenus news, insider Karen Valentine sold 8,358 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $3.46, for a total transaction of $28,918.68. Following the completion of the sale, the insider now directly owns 109,879 shares in the company, valued at approximately $380,181.34. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders have sold 20,514 shares of company stock valued at $70,978. 7.60% of the stock is owned by company insiders.
A number of large investors have recently added to or reduced their stakes in the business. Virtus Fund Advisers LLC bought a new stake in Agenus during the 4th quarter valued at about $320,000. BlackRock Inc. increased its stake in Agenus by 1.2% during the 4th quarter. BlackRock Inc. now owns 4,883,221 shares of the biotechnology company’s stock valued at $15,920,000 after purchasing an additional 55,759 shares in the last quarter. Candriam Luxembourg S.C.A. increased its stake in Agenus by 6.0% during the 4th quarter. Candriam Luxembourg S.C.A. now owns 655,000 shares of the biotechnology company’s stock valued at $2,135,000 after purchasing an additional 37,300 shares in the last quarter. North Star Asset Management Inc. bought a new stake in Agenus during the 4th quarter valued at about $222,000. Finally, Fisher Asset Management LLC increased its stake in Agenus by 33.8% during the 4th quarter. Fisher Asset Management LLC now owns 258,170 shares of the biotechnology company’s stock valued at $842,000 after purchasing an additional 65,270 shares in the last quarter. Institutional investors and hedge funds own 37.30% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://ledgergazette.com/2018/02/11/zacks-brokerages-expect-agenus-inc-agen-will-announce-quarterly-sales-of-15-58-million.html.
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.